AstraZeneca, Daiichi announce results from three trials on DATROWAY
Results from three trials continue to demonstrate the potential of DATROWAY in combination with various immunotherapies to improve outcomes in patients with non-small cell lung cancer, NSCLC, across multiple stages of the disease. These results from TROPION-Lung02, TROPION-Lung04 and NeoCOAST-2 were presented at the 2025 American Society of Clinical Oncology Annual Meeting. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate, ADC, discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (AZN). In 42 patients receiving first-line doublet DATROWAY plus pembrolizumab, an objective response rate of 54.8% was observed. In 54 patients receiving first-line triplet DATROWAY plus pembrolizumab and platinum chemotherapy, an ORR of 55.6% was observed. This analysis included patients enrolled during the dose escalation phase of the trial, where 4.8% and 40.7% of patients treated with the doublet and triplet regimens, respectively, received DATROWAY at a dose of 4 mg/kg versus 6 mg/kg. First results from cohort 5 of the TROPION-Lung04 phase 1b trial, presented during a poster session on Saturday, May 31, showed DATROWAY plus AstraZeneca's PD-1/TIGIT bispecific antibody rilvegostomig as a first-line treatment demonstrated an ORR of 57.5%, including one complete response and 22 partial responses in 40 patients with advanced or metastatic NSCLC. A disease control rate of 95% was seen. Final results from Arm 4 of the NeoCOAST-2 phase 2 platform trial evaluating neoadjuvant DATROWAY plus AstraZeneca's anti-PD-L1 therapy IMFINZI and single-agent platinum chemotherapy were presented during a poster session on Saturday, May 31 and showed the combination demonstrated a pathologic complete response rate of 35.2%
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
an hour ago
- USA Today
A new Lululemon dress is stirring up the internet. Here's why
A new Lululemon dress is stirring up the internet. Here's why "Is this just for the label? Who walks into Lululemon and they're like, 'Oh my gosh, that's the cutest summer dress I've ever seen?'" TikTok creator Dasie said. Show Caption Hide Caption Steven Madden to buy UK-based luxury shoe brand Kurt Geiger The world of fashion footwear has a new pair, as shoe designer Steven Madden said it would buy UK-based luxury brand Kurt Geiger. The all-cash deal, valued at $360 million, expands Steve Madden's presence in international markets. The internet is going crazy over a new dress, and no, it is not "the dress" from 2015. Behind the hysteria is a multi-functional athleisure maxi skirt-dress duo from trendy sportswear brand Lululemon. Lululemon's new 2-in-1 Maxi Dress, a basic one-color dress that can be worn as an ankle-length maxi skirt or strapless dress, has garnered mixed emotions from social media users. Some believe the nearly $150 dress is worth every penny because of its versatility, enough that the dress is sold out in every size except extra large, and others think it's undeserving of the hype. Interested to hear what people think? Here's what the internet is saying about the viral Lululemon 2-in-1 Maxi Dress. Viral trends: 10 years later, 'the dress' still divides us. But we understand a lot more about why. How much does Lululemon's 2-in-1 Maxi Dress cost? The 2-in-1 Maxi Dress costs $148 on the Lululemon website, before shipping. As of June 3, the dress was sold out in every size and color but Light Ivory in extra large. However, shoppers can sign up to be notified if and when the dress will be restocked on the Lululemon website. What are people saying about the dress? In a TikTok video with 83,000 views as of June 3, content creator Chantalissa models the dress, which she encourages her followers to buy. "It takes a lot for me to buy something that I see on TikTok, but the second I saw this 2-in-1 dress from Lululemon, I literally went to the store instantly and tried it on," Chantalissa said in her video. "I actually feel like a princess in it. It's so beautiful, so flowy. I'm obsessed." On the flip side, content creator Dasie expressed her confusion about the dress's popularity, specifically because of the price and simple design. "Is this just for the label? Who walks into Lululemon and they're like, 'Oh my gosh, that's the cutest summer dress I've ever seen?'" Dasie said in a TikTok video with about 4,800 views as of June 3. "I'm not trying to be mean. No hate. You could walk into Walmart and get a cuter dress than that." To 'thneed' or not to 'thneed' Lululemon's 2-in-1 Maxi Dress quickly became deemed a "thneed" on social media. A "thneed" is a garment that can be worn multiple ways, and its name comes from the highly versatile object knitted by the Once-ler in Dr. Seuss' "The Lorax." As depicted in the original Lorax book and movie, a "thneed" can be used as a shirt, sock, glove, hat, carpet or pillow − "a fine thing that all people need." In addition to being multifunctional, a "thneed" is cheap ($3.98, as outlined in "The Lorax") and ethically sourced, as "thneeds" are made entirely from foliage of Truffula Trees, the circular and wispy trees in the story. While some may believe the 2-in-1 Maxi Dress is a "thneed," TikTok user Rachael, commonly known as "the Thneed Girl," disagrees. "The garment really isn't transforming at all. It's just going from being worn down at the hip to up at like the chest. It's really not transforming like a thneed really needs to do," Rachael said in a TikTok video. "You can love this dress. You can hate this dress. You can make whatever arguments you want about the ethics of this dress, Lululemon as a company, I really don't care, but it's not a thneed." Greta Cross is a national trending reporter at USA TODAY. Story idea? Email her at gcross@
Yahoo
2 hours ago
- Yahoo
AstraZeneca (LSE:AZN) Reports Positive Trial Results For ENHERTU® In Breast Cancer Treatment
AstraZeneca recently announced promising clinical trial results for ENHERTU, which may reflect its ongoing commitment to enhancing therapeutic options for HER2-positive metastatic breast cancer. Over the last week, AstraZeneca's share price increased by 1%, aligning closely with the broader market's growth of 2%. While the company's recent product developments, including trials for ENHERTU and IMFINZI, and collaborations like the partnership with Danaher Corporation, underscore its innovation in oncology, these advancements likely added some weight to the overall market trend rather than significantly influencing the stock's performance in isolation. We've discovered 3 weaknesses for AstraZeneca that you should be aware of before investing here. The end of cancer? These 23 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. The recent news regarding AstraZeneca's advancements in oncology, including promising trial results for ENHERTU, may bolster their narrative of growth through innovation. These developments, alongside strategic collaborations, have the potential to enhance future revenue streams and earnings. While the 1% share price increase aligns with recent market trends, the longer-term picture reveals a more substantial total shareholder return of 44.76% over the past five years. During this period, AstraZeneca has demonstrated resilience, with performance reflected in their strategic expansions and R&D efforts. Within the last year, AstraZeneca did not match the broader UK market, which outperformed it with a 3.5% return compared to AstraZeneca's own performance. This highlights the importance of the company's strategic initiatives and their impact on maintaining competitiveness, particularly against market or industry trends. Looking forward, the news on ENHERTU and other developments might influence revenue and earnings projections positively. Analysts predict a 5.9% annual growth in revenue over the next three years, reaching $65.3 billion with earnings potentially hitting $13.5 billion by 2028. This growth trajectory could align with AstraZeneca's estimated fair value of £133.57, which marks a 19.7% increase from the current share price of £107.28. The consensus price target indicates potential upside, although it's crucial to consider prospective risks such as competitive pressures and regulatory changes. Click here to discover the nuances of AstraZeneca with our detailed analytical financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include LSE:AZN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
CNBC
2 hours ago
- CNBC
Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO
I'm back in New York City after spending the last weekend in Chicago for the American Society of Clinical Oncology annual meeting. More than 5,000 research abstracts were presented or published at ASCO by pharmaceutical giants, biotech companies, researchers and oncologists. They included studies on existing drugs, experimental treatments, AI tools and ideas for improving patient care. Here are some data highlights and executive commentary from the larger companies I follow: AstraZeneca wins big (again) – The blockbuster drug Enhertu from AstraZeneca and Japanese drugmaker Daiichi Sankyo stalled the growth of a common type of breast cancer by more than a year in a large late-stage trial when used as an initial treatment. The results could expand the use of the drug and change the way the disease is treated for the first time in a decade. The study evaluated Enhertu in combination with a standard medicine called pertuzumab as a frontline treatment, meaning it was used in patients newly diagnosed with what's known as HER2-positive metastatic breast cancer. Patients who got the Enhertu combination lived for almost 41 months before their disease spread, while a group who received a standard three-drug treatment lived for about 27 months before the cancer advanced. David Fredrickson, executive vice president of AstraZeneca's oncology business, told CNBC that one in three patients who start treatment for this type of cancer are not able to receive a second type of therapy because their health worsened or they died. But the results show that the Enhertu combination could give "another third of patients a chance to potentially have a longer progression-free survival time and to benefit from a more effective frontline therapy than if you wait till a second one." Pfizer impresses in colorectal cancer – The company's pill Braftovi, combined with two other cancer treatments, doubled survival time for patients with an aggressive form of colorectal cancer compared to a standard treatment in a late-stage trial. It's good news for Pfizer, which has submitted the data to the Food and Drug Administration to expand Braftovi's approval label. The three-treatment combination included a standard chemotherapy, an antibody drug called cetuximab and Braftovi, which targets a cancer mutation called BRAF V600E. That combination also cut deaths by 51% and slashed the risk that the cancer would progress by 47% compared to a standard treatment during the trial. Pfizer's Chief Scientific Officer Chris Boshoff told CNBC that 10% to 15% of colorectal cancer patients have that specific mutation, and noted their survival rates are "particularly poor." "We're very proud of [the data] because for the first time, it really shows a true impact on survival for a disease that's very challenging to treat," he said. Gilead and Merck combo's breast cancer win — The popular drug Trodelvy from Gilead in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment in a late-stage trial. Gilead could benefit from higher sales of Trodelvy as it competes with Enhertu. The study examined patients with advanced triple-negative breast cancer whose tumors express PD-L1, the protein targeted by drugs like Keytruda. Around 15% of breast cancer cases are triple negative, making them more aggressive and difficult to treat, according to Gilead. The findings suggest that the combination of Trodelvy and Keytruda "will likely become a new front-line standard of care in this setting," Dr. Jane Lowe Meisel, co-director of breast oncology at Emory University School of Medicine and a designated ASCO expert, said in a statement. A Merck, Daiichi Sankyo drug disappoints in lung cancer – Merck and Daiichi Sankyo on Thursday said they have withdrawn their U.S. application for an experimental treatment after it failed to prolong the lives of lung cancer patients in a late-stage trial. The drug, patritumab deruxtecan, is one of three so-called antibody drug conjugates that Merck has been working on with Daiichi Sankyo as it races to offset Keytruda's upcoming loss of exclusivity. The medication failed the trial's secondary goal of extending overall survival, which is defined as the length of time patients lived from the start of treatment. Those results, along with subsequent discussions with the FDA, led the companies to withdraw the application. But last year, the drug met the study's main goal of helping delay tumor progression compared to chemotherapy in patients who have been previously treated for non-small cell lung cancer with a mutation in a gene called EGFR. Marjorie Greene, Merck's head of oncology global clinical development, told CNBC that the "totality of the data couldn't support" the drug's application for approval. She called it a disappointment but noted that the company is learning from "what worked and what didn't work" and is still "fully investing" in refining the drug. Merck and Daiichi Sankyo plan on advancing the treatment into a late-stage development for breast cancer. Amgen's positive lung cancer data: The company's drug, Imdelltra, reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients whose disease had worsened after an initial round of chemotherapy, according to data from a late-stage trial. Imdelltra also extended median overall survival by more than five months compared to the standard-of-care chemotherapy. Amgen said the trial results are intended to support last year's accelerated approval of Imdelltra by the FDA. BONUS: Bristol Myers Squibb inks deal with BioNTech – Bristol Myers Squibb on Monday said it has agreed to pay up to $11.1 billion to partner with BioNTech and develop its next-generation cancer immunotherapy. The drug could take on Keytruda and new treatments in development by Summit Therapeutics and Pfizer. BioNTech is running late-stage studies on the drug in lung cancer and plans to start a phase three trial in triple-negative breast cancer this year. Feel free to send any tips, suggestions, story ideas and data to Annika at The FDA this week approved the first-ever AI platform for breast cancer prediction from Boston-based Clairity, marking a big milestone for women's health tech and potentially for women's health screening. I profiled Clairity's founder Dr. Connie Lehman three years ago, as part of a story on investment in Femtech. At the time, she told CNBC the accuracy of technology can help reduce over-screening for women who are presumed to be at risk, while helping to identify women who might otherwise not be monitored until they've already developed cancer. "By delivering validated, equitable risk assessments, we can help expand access to life-saving early detection and prevention for women everywhere," she said in the company's announcement of the approval. But to save lives, the next big step is to ensure women have access to the breakthrough technology as a preventive screening. The American Medical Association will first need to issue a billing code, which for some AI-driven tools has been slow to come. That code will be crucial to securing insurance coverage. Feel free to send any tips, suggestions, story ideas and data to Bertha at Amazon Pharmacy on Tuesday announced new updates for caregivers and more than 50 million Medicare Part D beneficiaries. Launched in 2020, Amazon Pharmacy was formed out of the company's 2018 acquisition of the online pharmacy PillPack. The offering is now a full-service, digital pharmacy that can help support patients with both one-off and recurring prescriptions. Prime members in cities like Los Angeles and New York City are eligible for same-day medication deliveries. Amazon said that customers with Medicare insurance can now directly access PillPack's services, which means those with two or more prescriptions can have their medications sorted into individual tear-away packets labeled with the date and time. The company said these monthly shipments will reduce the need for patients to keep track of multiple pill bottles and help them stick to their routines, according to a release. Patients interested in accessing pre-sorted medications through PillPack can sign up by logging into Amazon Pharmacy. Amazon Pharmacy also introduced a new way for verified caregivers to help manage medications on behalf of their loved ones. Around one in every five adults in the U.S. are caring for an aging family member, according to AARP. Patients can invite trusted caregivers to help oversee their medications by submitting their phone number. The caregiver will receive a text with a link, have to confirm details about the patient in question, and then can begin managing the patient's medications through their own account. "These updates deliver what our customers have been asking for—simpler medication management for themselves and their loved ones," John Love, vice president of Amazon Pharmacy, said in a statement on Tuesday. Amazon's online pharmacy is a part of the company's multi-year effort to push into the health-care industry. The company acquired primary care provider One Medical for roughly $3.9 billion in July 2022. Read the full announcement here. Feel free to send any tips, suggestions, story ideas and data to Ashley at
